Quick answers
- What is Vandetanib used for?
- The FDA-approved label (Caprelsa, Genzyme Corporation, April 23, 2026) says: “CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Vandetanib have a boxed warning?
- Yes. The FDA label for Caprelsa has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Vandetanib?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Vandetanib been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Vandetanib?
- 1 company lists prescription products of Vandetanib in the FDA NDC Directory, including Genzyme Corporation.
What Vandetanib is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. …
— FDA label: Caprelsa, Genzyme Corporation, effective April 23, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Caprelsa |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Genzyme Corporation2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022405 CAPRELSA | Genzyme Corp | April 6, 2011 | 18, latest January 27, 2026 2026: Labeling · 2025: REMS · 2025: REMS |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1098416, 1098418, 1114074, 1114096 |
|---|---|
| SPL set ID of the quoted label | e5721cb8-4185-47b9-bbb3-1c587e558a03 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA022405 |
| Active ingredients (FDA) | VANDETANIB |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Caprelsa, Genzyme Corporation, effective April 23, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →